상명이노베이션

01About us

02Platforms

03Pipelines

04Facilities

05Business

06News

07Contact us

Home > Pipelines > SMO SeriesSMO Series

SMO-IVT1

SMO-ICA1

SMO-ICL1

Indication

Macular Edema

Active Ingredient

Dexamethasone 700 mcg

Implant Size

0.46 X 6 mm

Administration

Intravitreal Injection

Milestones

* The release schedule of SMO-IVT1 and SMO-ICA1 is subject to change depending on the patent situation of each country

CEO : Jinha Park

Company : SANGMYUNG innovation Co., Ltd.

T : +82 2 3489 6100

Head Office : 2-27, Yeongmun-ro, Cheoin-gu, Yongin-si, Gyeonggi-do, Republic of Korea

Branch Office : 42, Seocho-daero 52-gil, Seocho-gu, Seoul, Republic of Korea